Guo Longhua, Zou Xiaofang, Gu Yinfang, Yi Lilan, Zhao Jingjing, Wu Guowu
Department of Medical Oncology, Cancer Center, Meizhou People's Hospital (Huangtang Hospital), Meizhou Hospital Affiliated to Sun Yat-Sen University, Meizhou, 514031, People's Republic of China.
Department of Biotherapy, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, People's Republic of China.
Onco Targets Ther. 2021 Mar 18;14:1989-1995. doi: 10.2147/OTT.S295067. eCollection 2021.
Chemotherapy is the mainstay of treatment for advanced small cell esophageal carcinoma (SCEC) characterized by poor prognosis. Preclinical studies demonstrated that apatinib has the potential to enhance the efficacy of conventional chemotherapeutic drugs and reverse multidrug resistance (MDR). This report described the application of apatinib combined with irinotecan as the third-line treatment for advanced SCEC in a 54-year-old male patient. His symptoms of upper abdominal pain and distension were ameliorated notably after the combination therapy. Computed tomography (CT) examination revealed the treatment efficacy was partial response (PR). The progression-free survival (PFS) and overall survival (OS) were 12.5 months and 28 months, respectively. The treatment-related toxicity was manageable. Apatinib combined with chemotherapy may serve as a new treatment choice for advanced SCEC patients. However, further studies should be conducted to confirm the therapeutic value of this combination regimen in advanced SCEC.
化疗是晚期小细胞食管癌（SCEC）的主要治疗方法，其预后较差。临床前研究表明，阿帕替尼有增强传统化疗药物疗效及逆转多药耐药（MDR）的潜力。本报告描述了阿帕替尼联合伊立替康作为一名54岁男性晚期SCEC患者三线治疗的应用情况。联合治疗后，他上腹部疼痛和腹胀的症状明显改善。计算机断层扫描（CT）检查显示治疗效果为部分缓解（PR）。无进展生存期（PFS）和总生存期（OS）分别为12.5个月和28个月。治疗相关毒性可控。阿帕替尼联合化疗可能成为晚期SCEC患者的一种新的治疗选择。然而，应开展进一步研究以证实这种联合方案在晚期SCEC中的治疗价值。
